CAT And Abbott Settle Humira Royalties Dispute
Cambridge Antibody Technologies and Abbott Laboratories have ended their protracted dispute over royalties for cholesterol drug Humira, reaching a settlement just one day before a lawsuit was scheduled to begin....To view the full article, register now.
Already a subscriber? Click here to view full article